Use of Strong Opioids in Advanced Cancer Pain: A Randomized Trial
|
|
- Eleanor Paul
- 5 years ago
- Views:
Transcription
1 Vol. 27 No. 5 May 2004 Journal of Pain and Symptom Management 409 Original Article Use of Strong Opioids in Advanced Cancer Pain: A Randomized Trial Franco Marinangeli, MD, Alessandra Ciccozzi, MD, Marco Leonardis, MD, Luca Aloisio, MD, Anna Mazzei, MD, Antonella Paladini, MD, Giampiero Porzio, MD, Paolo Marchetti, MD, and Giustino Varrassi, MD Departments of Anesthesiology and Pain Medicine (F.M., A.C., M.L., L.A., A.M., A.P., G.V.), and Oncology (G.P., P.M.), University of L Aquila, L Aquila, Italy Abstract The World Health Organization (WHO) guidelines for the treatment of cancer pain recommend nonopioid analgesics as first-line therapy, so-called weak analgesics combined with nonopioid analgesics as second-line therapy, and so-called strong opioids (with nonopioid analgesics) only as third-line therapy. However, these guidelines can be questioned with regard to the extent of efficacy as well as the rationale for not using strong opioids as first-line treatment, especially in terminal cancer patients. The purpose of this randomized study was to prospectively compare the efficacy and tolerability of strong opioids as first-line agents with the recommendations of the WHO in terminal cancer patients. One hundred patients with mild moderate pain were randomized to treatment according to WHO guidelines or to treatment with strong opioids. Evaluated outcomes included pain intensity, need for change in therapy, quality of life, Karnofsky Performance Status, general condition of the patient, and adverse events. No between-treatment differences were observed for changes in quality of life or performance status, but patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P 0.041). Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P 0.041). Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events. These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer. J Pain Symptom Manage 2004;27: U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. Key Words Oncologic pain, opioids, WHO guidelines Address reprint requests to: Franco Marinangeli, MD, Department of Anesthesiology and Pain Medicine, University of L Aquila, Piazzale S. Tommasi 1, L Aquila, Italy. Accepted for publication: October 13, U.S. Cancer Pain Relief Committee Published by Elsevier Inc. All rights reserved. Introduction Subsequent to the publication of the World Health Organization s (WHO) therapeutic ladder for the treatment of cancer pain 1 and its validation, 2 6 there has been criticism and debate regarding the evaluation and extent of efficacy of these guidelines. 7 With the emerging importance among physicians and patients of /04/$ see front matter doi: /j.jpainsymman
2 410 Marinangeli et al. Vol. 27 No. 5 May 2004 the need for more effective treatment of cancer pain, discussion among pain clinicians has focused on the appropriateness of initiating therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) or paracetamol (acetaminophen), as suggested by the WHO ladder, rather than on stronger analgesic agents such as opioids. Despite the known efficacy of opioids for cancer pain, there is only limited use of these drugs for this indication. The underutilization of opioids is in part based on the unsubstantiated fear by physicians, patients, and their families of opioid addiction and tolerance. Additionally, the strict regulation and control of these agents in most countries may present prescription difficulties, and legal problems arising from the actual or perceived abuse or addiction to these drugs can also contribute to their limited use. Consequently, it still occurs too often in the clinical setting that a terminal cancer patient presenting with strong pain is treated with massive doses of anti-inflammatory drugs or weak opioids. 8 The first two steps of the WHO guidelines are formally respected, but not the last one, thus raising the following issues regarding appropriate therapy: Is it reasonable to administer massive doses of NSAIDs or weak opioids in order to avoid strong opioids, thus achieving relative efficacy with a potentially greater incidence of side effects? What is the rationale for starting therapy in terminal patients with the weakest analgesic agents and avoiding the use of stronger more effective drugs? The purpose of this study was to try evaluate the use of strong opioids as first-line treatment in patients with terminal cancer and to compare this regimen with the recommended WHO guidelines that suggest the use of strong opioids only as third-line treatment. Methods The study was performed in accordance with the revised Declaration of Helsinki and the protocol was approved by the Ethics Committee of the study center involved. Both the physician and the patients were aware of the goals of the trial and written informed consent was obtained from each patient prior to enrollment and randomization. A total of 100 patients with a diagnosis of cancer, who were not eligible for disease-oriented treatment and were provided with home palliative care, were included in this open randomized study. The same oncologist defined the intractability of disease. In addition to the diagnosis of intractable cancer, inclusion criteria included a minimum age of 15 years and the presence of somatic or visceral pain having an untreated intensity of not greater than 6 on a 10 cm visual analogue scale (VAS; 0 no pain, 10 unbearable pain) over the last week. Exclusion criteria included the inability to perform follow-up, impaired sensory or cognitive function, and the use of strong opioids in a prior therapeutic step. Following a baseline evaluation, patients were randomly assigned to one of the two treatment groups. Patients in Group A were treated according to the WHO therapeutic ladder that utilizes nonopioid analgesics in Step I, so-called weak analgesics combined with nonopioid analgesics in Step II, and so-called strong opioids combined with nonopioid analgesics only in Step III. Patients assigned to Group B were immediately started on strong opioids, with dosages determined on a per case basis. The two treatment protocols were comparable because of the demonstrated efficacy of all the study drugs for VAS 6. In both groups, opioids could be combined with nonopioid analgesics. If immediate-release drugs were used, the evening dose was doubled in order to reduce the risk of nighttime pain breakthrough, and rescue medication in the form of higher dosage or additional drugs was available to treat incident pain. Co-analgesic drugs with indications different from pain were used in some cases because of a demonstrated efficacy in some painful syndromes. The choice of co-analgesic drugs was based on the specific characteristics of pain syndrome. The anticonvulsants, antidepressants, corticosteroids, bisphosphonates, and spasmolytic drugs were administered when neuropathic pain component, depression, edema associated with neoplastic lesion, osteolytic metastasis, and visceral spasms, respectively, were present. The predominance of neuropathic pain was a criterion for exclusion. Adjuvant drugs were prescribed for the treatment of cancer symptoms
3 Vol. 27 No. 5 May 2004 Use of Strong Opioids in Advanced Cancer Pain 411 or for the prophylaxis and/or treatment of side effects. A complete list of drugs used in the study is shown in Table 1. The least invasive route of administration (oral, transdermal patch) was always preferred, with subcutaneous or intravenous routes used only if necessary, such as in patients with dysphagia, persistent nausea and/or vomiting, ileus, or periods of transient mental distraction. The intrathecal route of administration was used only if oral or parenteral administration was ineffective or there were serious side effects not responsive to adjunctive therapy. In such cases, spinal opioids were combined with local anesthetics. If necessary, anesthetic and neurolytic blocks, psychotherapy, and physiotherapy were provided. Indications for neuroablative procedures were considered when pain was not controlled with noninvasive procedures or when the pharmacologic treatment was associated with intolerable side effects. In this case, the patient was excluded from the study. The necessity of palliative antineoplastic treatment (radiotherapy, Table 1 Analgesic, Co-Analgesic, and Adjuvant Drugs Used Drug Class Drug Systemic analgesics Nonopioids Weak opioids Strong opioids Co-analgesic drugs Anticonvulsants Antidepressants Corticosteroids Diphosphonates Spasmolytics Adjuvant drugs Antiemetics Anxiolytics Hypnotics Laxatives Prokinetics Neuroleptics paracetamol (acetaminophen) nimesulide diclofenac ibuprofen ketorolac codeine/acetaminophen tramadol buprenorphine fentanyl methadone morphine clonazepam carbamazepine gabapentin amitriptyline fluvoxamine dexamethasone pamidronate, butiscopolamine metoclopramide ondansetron diazepam flunitrazepam lactulose cisapride chlorpromazine haloperidol chemotherapy, hormonal therapy, or surgery) was assessed in collaboration with an oncologist. All patients were evaluated by the same pain clinician once a week, either as outpatients or, if the subject was not self-sufficient, during a home visit. The following parameters were evaluated at baseline, at each visit, and at any therapeutic change (change in drug or dosage): 1) patient s quality of life (QOL) by means of a multidimensional questionnaire; 9 2) side effects associated with treatment; 3) drug tolerability; 4) satisfaction with the analgesic treatment of the previous week (verbal report of satisfied or not satisfied in response to physician s query); and 5) Karnofsky Performance Status. 10 During periods of transient confusion, the QOL questionnaire and satisfaction score were omitted. Patients were also provided with a diary and requested to make a daily record of the following parameters:1) intensity of pain using a 10- cm VAS (0 no pain, 10 unbearable pain); 2) general condition using a 0 10-cm VAS (0 worst possible condition, 10 best possible condition); 3) occurrence of side effects or adverse events (the intensity was defined by a three point scale: 0 mild, 1 moderate, 2 severe); and 4) problems arising during the day. Only the side effects possibly linked to therapy and reported by the patients in their diary were registered by the pain physician. A responsible relative was also delegated the task of providing an evaluation on a daily basis in the same diary. The relative was requested to note his/her perception of the patient s overall condition on a 0 10-cm visual analogue scale (0 worst possible condition, 10 best possible condition). The study was considered concluded at the time of the patient death. Endpoints used to evaluate efficacy included: pain intensity (VAS), general condition (VAS), Karnofsky Performance Status, QOL, and patient satisfaction with the therapy of the previous week, number of weeks described as satisfactory, and incidence of therapeutic change. Data for the above endpoints were collected from the patient diary, records from the weekly visits, and at end of study. Mean values were obtained for the duration of treatment and were compared with baseline. Safety and tolerability were evaluated by comparing the type and incidence of side effects in the two groups, and discontinuation due to side effects.
4 412 Marinangeli et al. Vol. 27 No. 5 May 2004 Bivariate statistical analyses were performed by using chi-square and t-tests, as appropriate. P 0.05 was considered significant. Results Of the 100 patients enrolled, 8 were excluded (2 in Group A, 6 in Group B) for the following reasons: 3 patients (1 Group A, 2 Group B) for refusal to continue in the study; 2 patients (1 in each group) who underwent neuroablative therapy with subsequent pain resolution; 1 patient (Group B) who was lost to follow-up; and 2 patients (Group B) whose duration of treatment was less than 15 days. Thus, 48 patients who were treated according to the WHO guidelines (Group A) and 44 patients who were treated with strong opioids (Group B) are included in the analysis. The baseline demographic and disease characteristics of these patients are shown in Table 2; there were no significant differences between the two Table 2 Baseline and Disease Characteristics of Randomized and Treated Patients Group A Group B (n 48) (n 44) Age, years Mean SD Range Sex, % Male Female Diagnosis by organ system, % Respiratory Gastrointestinal/biliary Genito-urinary Musculoskeletal Primary site of pain, n Head/neck 2 1 Chest 7 5 Abdomen Back 12 7 Upper extremities 0 1 Lower extremities 8 9 Perineum 2 1 Duration of treatment, days mean ( SD) range Quality of life mean SD Karnofsky Performance Status Index, mean SD VAS pain score, mean SD groups. The cumulative evaluated weeks of treatment for all patients were 503 for Group A and 467 for Group B. The overall patient evaluation over the duration of treatment demonstrated significant reduction from baseline in Karnofsky Performance Status and disease-related QOL (Table 3). However, both treatment strategies resulted in significant improvements from baseline in pain intensity (VAS scores) (Table 3). Although these changes were similar in both treatment groups for QOL and performance status, firstline treatment with strong opioids (Group B) resulted in improvement in pain severity that was significantly better than that obtained in patients who were treated according to the WHO therapeutic ladder (Group A). Similarly, Group B was significantly superior to Group A for both the percentage of cumulative weeks that the patient defined treatment as satisfactory (85.6% vs. 80.5%, P 0.041), as well as for the percentage of cumulative weeks without a therapeutic change (48.9% vs. 59.3%, P 0.001) (Figure 1). The patient s general condition, assessed by the patients themselves using the VAS scale throughout the period of observation and recorded in the diary, was significantly better in Group B compared with Group A ( vs ; P 0.007). The condition of the patients in both groups according to the assessment by the responsible relative didn t show any statistically significant difference ( of Group B vs of Group A). The number of cumulative weeks during which a change in therapy was initiated was significantly lower in Group B (190 weeks) than in Group A (257 weeks; P 0.001). For Group A, 49.4% of the changes were drug switches, and 50.6% were changes in dosage. In contrast, Table 3 Mean Change from Baseline in the Overall Patient Evaluation Group A Group B P QOL ns Karnofsky ns Performance Status Pain intensity (VAS) Note: All changes reflect significant differences (P 0.05) from baseline; decreases in QOL and performance status indicate worsening condition, decrease in pain intensity indicates improvement.
5 Vol. 27 No. 5 May 2004 Use of Strong Opioids in Advanced Cancer Pain 413 Fig. 1. Percent of cumulative weeks that the patient defined treatment as satisfactory *P 0.041, and percent of cumulative weeks with no changes in therapy. **P Group B versus Group A. 96.3% of the changes in Group B were dosage changes, with only 3.7% of patients switching drugs (five patients switched from morphine to fentanyl and two patients switched from morphine to methadone). When a therapeutic change was initiated, both the pain intensity reported by the patient and the difference in the patient s general condition reported by the family member in the week after the change compared to the week before the change were significantly superior in Group B compared with Group A (Figure 2). In both groups, the change resulted in a significant reduction in pain intensity in the week after the change compared with the week prior to the change. However, only in Group B was there a significant improvement in the patient s general condition subsequent to the change in therapy (Figure 2). Several side effects considered to be related to therapy were reported by patients (Table 4). Of these events, only the incidence of nausea was significantly different between the two groups, being lower in Group A (315 episodes versus 437 episodes; P ). The type and mean dose of opioids being administered to patients at the time of death is shown in Table 5 for both groups. In the group treated using the WHO algorithm (Group A), half of the patients (48%) progressed to treatment with strong opioids. There wasn t any statistically significant difference in the dose of strong opioids required by the patients of both groups at the end of the study. No patients required any intrathecal analgesic administration or palliative antineoplastic treatment (radiotherapy, chemotherapy, hormonal therapy, or surgery). There were no statistically significant differences between the two study groups in the use of the co-analgesic drugs. No patient was treated with bisphosphonates. Discussion The problem in treating chronic pain, and cancer pain in particular, is not to finding effective therapies, but rather the appropriate choice and use of these therapies. All previous Fig. 2. Mean visual analogue scale scores (VAS) of pain intensity reported by the patient and general condition reported by the patient s relative in the week preceding and subsequent to a change in therapy. Note that a higher value in VAS for pain denotes increased pain, whereas a higher value for the general condition denotes improvement. *P versus previous week; P versus Group A.
6 414 Marinangeli et al. Vol. 27 No. 5 May 2004 Table 4 Episodes of Side Effects Possibly Linked to Therapy and Reported by Patients in Their Diaries Number of Events Adverse Event Group A Group B Nausea 315 a 437 Vomiting Constipation Gastro-enteric bleeding 2 0 Periods of mental confusion (excluding the period immediately before death) P versus Group B. efficacy assessments of the WHO step ladder have been case control studies or retrospective reviews of patients files, but not randomized trials. This is a randomized, but not a doubleblind, study, with the aim to compare two different methods of treatment. A double-blind study is particularly difficult to realize when a number of drugs, with different routes of administration and different delivery systems are used. It could be more feasible when only two drugs are compared. In 1998, Grond et al. underlined that the use of weak opioids has great educational impact and has helped spread the use of the WHO guidelines. 11 Furthermore, weak opioids are more freely available and are expected to have a better side-effect profile. At the same time, they stated the necessity of controlled long-term studies for confirmation. The results of the current study demonstrated the potential efficacy but questionable tolerability and acceptability of NSAIDs alone and in combination with weak opioids for the treatment of mild and/or moderate pain in terminal cancer patients. It is important to underline the choice of VAS score as inclusion criteria. It was justified by the main goal of the study: the feasibility to use strong opioids from Table 5 Type and Mean Dose ( SD) of Opioid Being Administered at Time of Death Opioid Group A (n) Group B (n) Tramadol (mg/d) (13) Codeine (mg/d) (12) Morphine (mg/d) (12) (15) Fentanyl TTS (µg/h) (8) (23) Methadone (mg/d) (3) (6) the beginning of the symptoms (mild and moderate pain), and to make the groups homogeneous. Moreover, the necessity of strong opioids in the treatment of severe pain (VAS 7) is well established in the literature and suggested by WHO. Given a less intense pain, strong opioids appear to be at least as effective and better tolerated. This was demonstrated not only by significantly superior pain relief, but also by the significantly greater number of weeks of patient satisfaction and fewer therapeutic changes among patients treated with strong opioids as first line pain therapy. This superiority is especially important in the treatment of patients affected by an advanced disease and for whom disease-oriented treatment is not likely to be an option. These patients are often in the worst possible physical condition and are at risk for the side effects of drugs, such as NSAIDs, which have a narrow therapeutic range. Although there are no established guidelines for the definition of disease intractability, in this study the evaluation was always performed by the same oncologist, on the basis of clinical evaluation and response to therapy. The present study also evaluated the concept of patient QOL. This concept may be difficult to recognize in terminal cancer patients, but endof-life QOL has become increasingly important in the management of such patients, and may also be considered to be the basis of palliative care. Although the instrument used in this study may capture disease-related physical components of QOL based on its use of health-related questions, the non-specific VAS scales used to assess the patient s general condition, both from the patient s and the relative s perspective, may capture non-physical aspects of QOL. These scales provide a useful instrument because of their ease and rapidity of use on a daily basis. 7,9 12 Although there was deterioration from baseline in the Karnofsky Performance Status and QOL, as might be expected in this population of patients, the magnitude of deterioration was similar with both treatment strategies. Despite the reduction in these endpoints, the reduction in pain and the greater patient satisfaction in Group B support the use of strong opioids at an appropriate dosing schedule. Additionally, the lack of improvement in the patients general condition following a therapeutic change in Group A would suggest that
7 Vol. 27 No. 5 May 2004 Use of Strong Opioids in Advanced Cancer Pain 415 treatment with weak opioids may cause patient discomfort, at least during the week following the change. This does not occur in the group of patients treated with strong opioids, probably because of continuous titration, which is related to disease evolution; the majority of the therapeutic changes in Group B were related to changes in dose rather than change in drug (96.3% vs. 3.7%). In a rapidly worsening pathology, the use of drugs with a limited range of therapeutic efficacy can potentially increase the risk of ineffective treatment and continuous changes in dosage. In the group treated according to the WHO guidelines, the overall therapeutic efficacy was good during the entire disease evolution, consistent with the studies that validating the WHO guidelines. However, this therapeutic efficacy was still significantly lower compared to the efficacy of patients initiated on treatment with strong opioids. Furthermore, the wide range of strong opioids currently available in a range of doses and routes of administration, suggests the possibility of effective and well-tolerated treatment with strong opioids even for mild/ moderate pain. Although a 0.69 difference in change pain intensity could seem clinically not important, it could influence the therapeutic choice, especially when WHO guidelines are used. Because of physician fear of administering strong opioids, the prescription of nonopioid drugs (e.g., NSAIDs) or of weak opioids at the highest dosages, may result in the occurrence of side effects, which may present a greater risk to the patient than that of strong opioids. Although this study was not powered to show statistically significant differences in uncommon but serious side effects, the worst side effects were noted with the use of NSAIDs (two bleeding ulcers). This is consistent with the known gastrointestinal toxicity of these drugs. 11,13,14 Only the incidence of the nausea was significantly higher in Group A patients. This result could be related both to the analgesic drugs and higher pain intensity. One of the aims of the study was to assess the incidence of tolerance or addiction to strong opioids in incurable patients. The potential for tolerance and addiction and the possible induction of respiratory depression represent the main barriers to the use of these drugs in countries such as Italy, where the use of opioids for analgesic purposes remains low. 15 During the current study, there was an increase in the consumption of strong opioids in Group B, but, as showed by Schug et al. in a long-term survey of morphine in cancer pain patients, this result could be explained by progression of the terminal disease. 16 Despite this increase in consumption, the dose of these drugs was generally lower than patients in Group A who progressed to strong opioids, although these differences were not statistically significant. It has been demonstrated that tolerance is a relative problem, because in many patients even with very severe pain, it is only necessary to increase the initial dosage only during the process of disease evolution. 17 This has been confirmed in the current study during which the physician was always able to attribute the increase in dosages to disease progression. It should also be noted that no patient attained dose levels of analgesics responsible for tolerance; continuous dose modifications were always performed in order to follow disease evolution. Furthermore, the short period of survival together with the combination of effective adjuvant drugs may also eliminate fears of tolerance and addiction. Finally, with regard to the fear of respiratory depression, it should be stressed that morphine is actually indicated as a useful adjuvant drug in the control of respiratory symptoms associated with heart failure and myocardial infarction. 18 The present study also assessed disease evolution based on the evaluation of the patient s relative during therapeutic changes. This may be of particular clinical importance because the physician often complies with the requests of such a person rather than with those of the patient, who sometimes accepts pain or is unable to express his/her opinion. Although several studies have suggested that there is a tendency of relatives to overestimate pain, 19,20 other studies have demonstrated that the perception of a relative may provide a more accurate index of the patient s conditions. 21,22 In summary, the data obtained in this study support the fundamental assertions of the WHO guidelines. Nevertheless, such guidelines exclude disease progression and this may prove to be a limitation. In fact, there are often situations where the disease quickly evolves and where therapeutic changes may not be tolerated by
8 416 Marinangeli et al. Vol. 27 No. 5 May 2004 the patient and his/her relatives. Consequently, it may be necessary to modify these guidelines to take into account both disease outcomes and patient-centered outcomes. The data from this study should further reassure the physician about the need and use of strong opioids in appropriate circumstances. Moreover, the quick progression of disease, reduced life-expectancy, and the demonstrated safety of opioid analgesics are reason enough to administer strong opioids in all incurable oncologic patients, independent of the intensity of pain. Strong opioids, because of their wide therapeutic efficacy and tolerability, should be considered as a very important instrument in the ethical care of the intractable patient. References 1. World Health Organization. Cancer pain relief. Geneva: World Health Organization, Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1987;59: Schug SA, Zech D, Dörr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5: Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991;6: Grond S, Zech D, Lynch J, et al. Validation of World Health Organization guidelines for pain relief in head and neck cancer. A prospective study. Ann Otol Rhinol Laryngol 1993;102: Zech D, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63: Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274: Cascinu S, Giordani P, Agostinelli R, et al. Pain and its treatment in hospitalized patient with metastatic cancer. Supp Care Cancer 2003;11: Ferrell BR, Wisdom C, Wenzl C. Quality of life as an outcome variable in the management of cancer pain. Cancer 1989;63: Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990; 65: Grond S, Meuser T. Weak opioids an educational substitute for morphine? Curr Opin Anaesthesiol 1998;11: Donnelly S, Rybicki L, Walsh D. Quality of life measurement in the palliative management of advanced cancer. Support Care Cancer 2001;9: García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343: Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990 s. Arch Intern Med 2000;160: Blengini C, Ventafridda V. Use and cost of opioids in Italy. J Pain Symptom Manage 2000;20: Schug SA, Zech D, Grond S, et al. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992;7: Brescia FJ, Portenoy RK, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992;10:149v Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol 1999;10: Lobchuk MM, Kristjanson L, Degner L, et al. Perceptions of symptom distress in lung cancer patients: I. Congruence between patients and primary family caregivers. J Pain Symptom Manage 1997;14: Kristjanson LJ, Nikoletti S, Porock D, et al. Congruence between patients and family caregivers perceptions of symptom distress in patients with terminal cancer. J Palliat Care 1998;14: Dar R, Beach CM, Barden PL, Cleeland CS. Cancer pain in the marital system: a study of patients and their spouses. J Pain Symptom Manage 1992;7: Lin CC. Congruity of cancer pain perceptions between Taiwanese patients and family caregivers: relationship to patients concerns about reporting pain and using analgesics. J Pain Symptom Manage 2001; 21:18 26.
Low Morphine Doses in Opioid-Naive Cancer Patients with Pain
242 Journal of Pain and Symptom Management Vol. 31 No. 3 March 2006 Original Article Low Morphine Doses in Opioid-Naive Cancer Patients with Pain Sebastiano Mercadante, MD, Gianpiero Porzio, MD, Patrizia
More informationTHE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT
1 THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT Jaegtvolden 4-5 June 2012 14. 12. 2012 2 1 3 WHO ANALGESIC LADDER (1996) NSAID +/- Adjuvant STEP II OPIODS Opids for mild to moderate
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationModule 2 Pain Management. Handouts. Pain Is... Please click the links button under the video. You can print and/or save the handouts.
E L N E C End-of-Life Nursing Education Consortium SuperCore Curriculum Module 2 Pain Management Handouts Please click the links button under the video. You can print and/or save the handouts. Pain Is...
More informationSafety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
Vol. 32 No. 2 August 2006 Journal of Pain and Symptom Management 175 Original Article Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationPain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017
Pain management in Paediatric Palliative Care Dr Jane Nakawesi 14 th August 2017 Content Management of pain in children Non pharmacological Pharmacological Exit level outcomes The participants will: Know
More information10/08/59 PAIN IS THE MOST COMMON TREATABLE SYMPTOM OF CANCER CURRENT EVIDENCE BASED CONCEPTS: MANAGEMENT OF CANCER PAIN PAIN AN UNMET CLINICAL NEED IN
Pain is a frequent complication of cancer, and is common in many other life-limiting illnesses MANAGEMENT OF CANCER PAIN A/Prof Ghauri Aggarwal FRACP, FAChPM, FFPMANZCA Palliative Medicine Physician Sydney
More informationSCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults BACKGROUND The justification for developing these guidelines lies
More informationCancer Pain. Suresh K Reddy, MD,FFARCS The University of Texas MD Anderson Cancer Center
Cancer Pain Suresh K Reddy, MD,FFARCS The University of Texas MD Anderson Cancer Center Prevalence of the Most Common Symptoms in Advanced Cancer (1000 Adults) Symptom % Symptom % Pain 82 Lack of Energy
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationManagement of cancer pain
DOI 10.1007/s11739-010-0448-8 SYMPOSIUM: MANAGING OF COMPLICATIONS IN PATIENTS WITH CANCER Management of cancer pain Sebastiano Mercadante Ó SIMI 2010 Abstract In the last decades, studies validating the
More informationPALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST
PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 22 AUGUST 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients Sebastiano Mercadante, Patrizia
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationPain control in Cancer patients. Dr Ali Shoeibi, Assistant Professor of Neurology
Pain control in Cancer patients Dr Ali Shoeibi, Assistant Professor of Neurology More than two thirds of patients with advanced cancer experience cancer pain Almost all pain can be controlled to some extent
More informationComplicated pain. Dr Stephanie Lippett
Complicated pain Dr Stephanie Lippett UK incidence & prevalence of cancer pain 1% of UK population are living with cancer at present 70% of cancer patients experience pain 70-90% of patients with advanced
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationAssociate Professor Supranee Niruthisard Department of Anesthesiology Faculty of Medicine Chulalongkorn University January 21, 2008
Associate Professor Supranee Niruthisard Department of Anesthesiology Faculty of Medicine Chulalongkorn University January 21, 2008 PAIN MECHANISMS Somatic Nociceptive Visceral Inflammatory response sensitizes
More informationGUIDELINEs ON PAIN MANAGEMENT IN UROLOGY
GUIDELINEs ON PAIN MANAGEMENT IN UROLOGY (Text update March 2009) P. ader (chair), D. Echtle, V. Fonteyne, G. De Meerleer, E.G. Papaioannou, J.H. Vranken General principles of cancer pain management The
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationManaging Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN
Managing Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN Oncology Clinical Nurse Specialist, Senior Research Specialist City of Hope Definition of Pain Pain is an unpleasant sensory and emotional
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationGUIDELINES ON PAIN MANAGEMENT IN UROLOGY
GUIDELINES ON PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationPalliative and Hospice Care of the Terminally Ill Introduction
Palliative and Hospice Care of the Terminally Ill Introduction There has been an increase in life expectancy for men and women of all races to 77.6 years Leading causes of death in older patients are chronic
More informationPain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17
Pain Christine Illingworth Community Nurse St Luke s Hospice 17/5/17 What is pain? Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain is whatever
More informationEnhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice
Enhanced Community Palliative Support Services Lynne Ghasemi St Luke s Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationOpioid-induced or pain relief-reduced symptoms in advanced cancer patients?
European Journal of Pain 10 (2006) 153 159 www.europeanjournalpain.com Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Sebastiano Mercadante a,b, *, Patrizia Villari a, Patrizia
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationPAIN MANAGEMENT IN UROLOGY
24 PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional experience
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationOPIOIDS ARE THE MAINSTAY of moderate to severe
Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine By Sebastiano Mercadante, Alessandra Casuccio, and Luciano Calderone OPIOIDS ARE THE MAINSTAY of moderate to
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationIndex. Surg Clin N Am 85 (2005) Note: Page numbers of article titles are in boldface type.
Surg Clin N Am 85 (2005) 393 398 Index Note: Page numbers of article titles are in boldface type. A Acetaminophen, for chronic pain, in surgical patients, 219 a2 Adrenergic agonists, for neuropathic pain,
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationSharon A Stephen, PhD, ARNP, ACHPN. September 23, 2014
Sharon A Stephen, PhD, ARNP, ACHPN September 23, 2014 Case-based presentation selected to discuss: Pain assessment Barriers to adequate pain relief Pharmacologic interventions Non-Pharmacologic interventions
More informationOPIOIDS AND NON-CANCER PAIN
Ch05.qxd 1/6/04 4:33 PM Page 77 CHAPTER 5 OPIOIDS AND NON-CANCER PAIN Background 78 Side-effects of opioids 78 Tolerance, physical dependence and addiction 79 Opioid-induced pain 79 Practical issues 80
More informationPain Assessment & Management. For General Nursing Orientation
Pain Assessment & Management For General Nursing Orientation April 2012 Overview Definition of pain Barriers to effective pain management Types of pain Objective pain assessment Approaches to management
More informationSprays for pain management as an alternative to injection and other routes of administration
Prescription Division Sprays for pain management as an alternative to injection and other routes of administration A scientific roundtable hosted by Aptar Pharma Prescription Division Delivering solutions,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kelley AS, Morrison RS. Palliative care for the seriously ill.
More informationAnalysis and Treatment of Different Types of Neuropathic Cancer Pain
Vol. 26 No. 6 December 2003 Journal of Pain and Symptom Management 1123 Original Article Analysis and Treatment of Different Types of Neuropathic Cancer Pain Petra Stute, MD, Jens Soukup, MD, Matthias
More informationE-Learning Module N: Pharmacological Review
E-Learning Module N: Pharmacological Review This Module requires the learner to have read Chapter 13 of the Fundamentals Program Guide and the other required readings associated with the topic. Revised:
More informationOpioids in the Management of Chronic Pain: An Overview
Opioids in the Management of Chronic Pain: An Overview Appropriate treatment of chronic pain may include both pharmacologic and non-pharmacologic modalities. The Board realizes that controlled substances,
More informationFDA hormone replacement therapy Web site 6
TABLE OF CONTENTS Caring for pain at UIMCC 1-5 FDA hormone replacement therapy Web site 6 P&T Committee Formulary Action - September 2003 6 Caring for pain at UIMCC The International Association for the
More informationDigital RIC. Rhode Island College. Linda M. Green Rhode Island College
Rhode Island College Digital Commons @ RIC Master's Theses, Dissertations, Graduate Research and Major Papers Overview Master's Theses, Dissertations, Graduate Research and Major Papers 1-1-2013 The Relationship
More informationPain Management Strategies Webinar/Teleconference
Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits
More informationOptimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management
Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management Eric Roeland, MD GI Oncology Palliative Medicine Pancreatic Cancer Patient Tool Belt Chemotherapy Surgery Pain & Symptom
More informationInitial Dose Cascade of TTS Fentanyl with Proper Adjuvant Medications in Cancer Pain
J Korean Med Sci 2003; 18: 733-7 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Initial Dose Cascade of TTS Fentanyl with Proper Adjuvant Medications in Cancer Pain According to the three
More informationSedation for Refractory Symptoms of Terminal Cancer Patients in Taiwan
Vol. 21 No. 6 June 2001 Journal of Pain and Symptom Management 467 Original Article Sedation for Refractory Symptoms of Terminal Cancer Patients in Taiwan Tai-Yuan Chiu, MD, MHSci, Wen-Yu Hu, RN, MSN,
More informationOpioid Escalation in Patients with Cancer Pain: The Effect of Age
Vol. 32 No. 5 November 2006 Journal of Pain and Symptom Management 413 Original Article Opioid Escalation in Patients with Cancer Pain: The Effect of Age Sebastiano Mercadante, MD, Patrizia Ferrera, MD,
More informationPain is a more terrible Lord of mankind than even death itself.
CHRONIC OPIOID RX FOR NON-MALIGNANT PAIN Gerald M. Aronoff, M.D., DABPM Med. Dir., Carolina Pain Assoc Charlotte, North Carolina, USA Pain Pain is a more terrible Lord of mankind than even death itself.
More informationChoose a category. You will be given the answer. You must give the correct question. Click to begin.
Instructions for using this template. Remember this is Jeopardy, so where I have written Answer this is the prompt the students will see, and where I have Question should be the student s response. To
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationObjectives. What is pain? 9/27/2017. Pain: Does this Hurt? Fall 2017 Dean Fox, MD, FACP
Pain: Does this Hurt? Fall 2017 Dean Fox, MD, FACP Photo credit: http://multiple-sclerosis-research.blogspot.com/2013/10/pain-and-unemployment.html Objectives Consider personal goal of pain management
More informationPatients and Relatives Perceptions About Intravenous and Subcutaneous Hydration
354 Journal of Pain and Symptom Management Vol. 30 No. 4 October 2005 Original Article Patients and Relatives Perceptions About Intravenous and Subcutaneous Hydration Sebastiano Mercadante, MD, Patrizia
More informationNOVIDADES NO TRATAMENTO COM OPIOIDES. Novelties in therapeutic with opioids. V Congresso National de Cuidados Palliativos Marco 2010, Lisboa
NOVIDADES NO TRATAMENTO COM OPIOIDES Novelties in therapeutic with opioids V Congresso National de Cuidados Palliativos 11 12 Marco 2010, Lisboa Friedemann Nauck Department Palliative Medicine Center Anesthesiology,
More informationNociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation
Learning Objectives Effective, Safe Analgesia An Approach to Appropriate Outpatient Chronic Pain Treatment By the end of this presentation, participants will be able to: Identify multiple factors that
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBreakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights
Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights Steven Wong, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, UCLA David Geffen School of Medicine
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationPancreatic cancer Palliative Care
Pancreatic cancer Palliative Care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Pall Care Serbia, Belgrade Pancreatic Cancer: Palliative Care Abdominal / epigastric
More informationNebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study
Vol. 29 No. 6 June 2005 Journal of Pain and Symptom Management 613 Clinical Note Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study Eduardo Bruera, MD, Raul Sala,
More informationObjectives. Statistics 9/16/2013. The challenge of climbing Mt. Everest: Malignant pain management in the opioid tolerant patient
The challenge of climbing Mt. Everest: Malignant pain management in the opioid tolerant patient Holly Swensen, MSN, APRN NP c, RN BC Pain Management St. Alphonsus Regional Medical Center Cancer Care Center
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More information1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective
Cancer Related Pain: Case-Based Pharmacology Jeannine M. Brant, PhD, APRN, AOCN Oncology Clinical Nurse Specialist Nurse Scientist Billings Clinic Conflicts of Interest Jeannine Brant has served on the
More informationDisclosures. Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals
Anne F. Walsh, MSN, ANP BC, ACHPN, CWOCN Kathleen Broglio, MN, ANP BC, ACHPN, CPE Disclosures Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals
More informationOpioid Management Change Package 2017/2018
Opioid Management Change Package 2017/2018 Opioid Prescribing and Management Overall 100% 80% 60% 40% 20% 0% 01/07/2016 01/08/2016 01/09/2016 01/10/2016 01/11/2016 01/12/2016 01/01/2017 01/02/2017 01/03/2017
More informationManaging Care at End of Life:
Managing Care at End of Life: Physical Suffering Pain & Dyspnea Verna Sellers, MD, MPH, AGSF Medical Director Centra PACE Lynchburg, Virginia 1 Speaker Disclosures: Dr. Sellers has disclosed that she has
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationPsychology of Pain DR. ARNEL BANAGA SALGADO,
Psychology of Pain DR. ARNEL BANAGA SALGADO, Doctor of Psychology (USA) FPM (Ph.D.) Psychology (India) Doctor of Education (Phl) Master of Arts in Nursing (Phl) Master of Arts in Teaching Psychology (PNU)
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationPain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan
Pain management in palliative care Dr. Stepanie Lippett and Sister Karen Davies-Linihan contents Concept of total pain Steps in pain management Recognising neuropathic pain WHO analgesic ladder Common
More informationBreakthrough Pain in Oncology: A Longitudinal Study
Vol. 40 No. 2 August 2010 Journal of Pain and Symptom Management 183 Original Article Breakthrough Pain in Oncology: A Longitudinal Study Sebastiano Mercadante, MD, Vittoria Zagonel, MD, Enrico Breda,
More informationThe World Health Organization has developed and has widely accepted an algorithm for treatment of cancer pain. This is described as the three-step lad
Hello. My name is Cynthia Abarado. I m an Advanced Practice Nurse at the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. I am going to present to you
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationPAIN MANAGEMENT 101. By: Vicki McCulloch RN, NP & DeAnna Looper RN, CHPN, CHPCA
PAIN MANAGEMENT 101 By: Vicki McCulloch RN, NP & DeAnna Looper RN, CHPN, CHPCA Objectives Identify a step-wise approach to pain management. Identify the WHO Pain Ladder. Identify non-pharmacological pain
More informationIntravenous Fentanyl for Cancer Pain: A Fast Titration Protocol for the Emergency Room
876 Journal of Pain and Symptom Management Vol. 26 No. 3 September 2003 Clinical Note Intravenous Fentanyl for Cancer Pain: A Fast Titration Protocol for the Emergency Room Luiz Guilherme L. Soares, MD,
More informationPain Management During Endof-life
Pain Management During Endof-life The more that we understand about how pain works and how to relieve this suffering, the gentler and easier we can make end-of-life for patients who are suffering from
More informationThe pain of it all. Rod MacLeod MNZM. Hibiscus Hospice, Auckland and University of Auckland
The pain of it all Rod MacLeod MNZM Hibiscus Hospice, Auckland and University of Auckland Definition of PAIN An unpleasant sensory and emotional experience which we primarily associate with tissue damage
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationPostoperative pain management: Analgesics, algorithms and patient activation
Postoperative pain management: Analgesics, algorithms and patient activation Alfred Deakin Prof. Mari Botti Deakin University/Epworth HealthCare Victorian Perioperative Nurses Group 60 th State Conference,
More informationCeliac Plexus Block for Pancreatic Cancer Pain: Factors Influencing Pain, Symptoms and Quality of Life
1140 Journal of Pain and Symptom Management Vol. 26 No. 6 December 2003 Original Article Celiac Plexus Block for Pancreatic Cancer Pain: Factors Influencing Pain, Symptoms and Quality of Life Sebastiano
More informationConstipation Management in Palliative Care: A Survey of Practices in the United Kingdom
238 Journal of Pain and Symptom Management Vol. 29 No. 3 March 2005 Original Article Constipation Management in Palliative Care: A Survey of Practices in the United Kingdom Margaret Goodman, RN, DipNurs,
More information16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces
16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces Moderators: Kendra Grim, MD, Robert T. Wilder, MD, PhD Institution:
More informationPersistent Pain Resources. Educational Slide Set
Persistent Pain Resources Educational Slide Set October 216 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationCauses of Admission to A Palliative Care Inpatient Unit in An Egyptian Cancer Center
Med. J. Cairo Univ., Vol. 78, No. 2, December: 585-589, 2010 www.medicaljournalofcairouniversity.com Causes of Admission to A Palliative Care Inpatient Unit in An Egyptian Cancer Center KHALED M. GALAL,
More informationSyllabus. Questions may appear on any of the topics below: I. Multidimensional Nature of Pain
Questions may appear on any of the topics below: I. Multidimensional Nature of Pain Syllabus A. Epidemiology 1. Pain as a public health problem with social, ethical, legal and economic consequences 2.
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationGuidelines on the Safe Practice of Acute Pain Management
Page 1 of 7 Guidelines on the Safe Practice of Acute Pain Version Effective Date 1 1 MAY 1994 (Reviewed Feb 2002) 2 1 DEC 2014 Document No. HKCA P11 v2 Prepared by College Guidelines Committee Endorsed
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More information